Research ExplorerPublicationsMultigene Assays for Classification, Prognosis, and Predicti...

Multigene Assays for Classification, Prognosis, and Prediction in Breast Cancer

Standard

Multigene Assays for Classification, Prognosis, and Prediction in Breast Cancer : a Critical Review on the Background and Clinical Utility. / Sinn, P; Aulmann, S; Wirtz, R; Schott, S; Marmé, F; Varga, Z; Lebeau, A; Kreipe, H; Schneeweiss, A.

In: GEBURTSH FRAUENHEILK, Vol. 73, No. 9, 01.09.2013, p. 932-940.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Sinn, P, Aulmann, S, Wirtz, R, Schott, S, Marmé, F, Varga, Z, Lebeau, A, Kreipe, H & Schneeweiss, A 2013, 'Multigene Assays for Classification, Prognosis, and Prediction in Breast Cancer: a Critical Review on the Background and Clinical Utility', GEBURTSH FRAUENHEILK, vol. 73, no. 9, pp. 932-940. https://doi.org/10.1055/s-0033-1350831

APA

Sinn, P., Aulmann, S., Wirtz, R., Schott, S., Marmé, F., Varga, Z., Lebeau, A., Kreipe, H., & Schneeweiss, A. (2013). Multigene Assays for Classification, Prognosis, and Prediction in Breast Cancer: a Critical Review on the Background and Clinical Utility. GEBURTSH FRAUENHEILK, 73(9), 932-940. https://doi.org/10.1055/s-0033-1350831

Vancouver

Sinn P, Aulmann S, Wirtz R, Schott S, Marmé F, Varga Z et al. Multigene Assays for Classification, Prognosis, and Prediction in Breast Cancer: a Critical Review on the Background and Clinical Utility. GEBURTSH FRAUENHEILK. 2013 Sep 1;73(9):932-940. https://doi.org/10.1055/s-0033-1350831

Bibtex

@article{10baafa2ab4e450c99bc54819078a5f2,
title = "Multigene Assays for Classification, Prognosis, and Prediction in Breast Cancer: a Critical Review on the Background and Clinical Utility",
abstract = "Gene signatures which are based on multigene profiling assays have been developed for the purpose to better define the prognosis and prediction of therapy results in early-stage breast cancer. These assays were designed to be more specific than conventional clinico-pathologic parameters in the selection of patients for (neo-)adjuvant treatment and in effect help to avoid unnecessary cytotoxic treatment. In this review we describe molecular risk scores, for which tests are commercially available (PAM50{\textregistered}, MammaTyper{\textregistered}, MammaPrint{\textregistered}, Oncotype DX{\textregistered}, Endopredict{\textregistered}, Genomic Grade Index{\textregistered}) and IHC risk scores (Mammostrat{\textregistered} and IHC4), and discuss the current evidence of their clinical use.",
author = "P Sinn and S Aulmann and R Wirtz and S Schott and F Marm{\'e} and Z Varga and A Lebeau and H Kreipe and A Schneeweiss",
year = "2013",
month = sep,
day = "1",
doi = "10.1055/s-0033-1350831",
language = "English",
volume = "73",
pages = "932--940",
journal = "GEBURTSH FRAUENHEILK",
issn = "0016-5751",
publisher = "Georg Thieme Verlag KG",
number = "9",

}

RIS

TY - JOUR

T1 - Multigene Assays for Classification, Prognosis, and Prediction in Breast Cancer

T2 - a Critical Review on the Background and Clinical Utility

AU - Sinn, P

AU - Aulmann, S

AU - Wirtz, R

AU - Schott, S

AU - Marmé, F

AU - Varga, Z

AU - Lebeau, A

AU - Kreipe, H

AU - Schneeweiss, A

PY - 2013/9/1

Y1 - 2013/9/1

N2 - Gene signatures which are based on multigene profiling assays have been developed for the purpose to better define the prognosis and prediction of therapy results in early-stage breast cancer. These assays were designed to be more specific than conventional clinico-pathologic parameters in the selection of patients for (neo-)adjuvant treatment and in effect help to avoid unnecessary cytotoxic treatment. In this review we describe molecular risk scores, for which tests are commercially available (PAM50®, MammaTyper®, MammaPrint®, Oncotype DX®, Endopredict®, Genomic Grade Index®) and IHC risk scores (Mammostrat® and IHC4), and discuss the current evidence of their clinical use.

AB - Gene signatures which are based on multigene profiling assays have been developed for the purpose to better define the prognosis and prediction of therapy results in early-stage breast cancer. These assays were designed to be more specific than conventional clinico-pathologic parameters in the selection of patients for (neo-)adjuvant treatment and in effect help to avoid unnecessary cytotoxic treatment. In this review we describe molecular risk scores, for which tests are commercially available (PAM50®, MammaTyper®, MammaPrint®, Oncotype DX®, Endopredict®, Genomic Grade Index®) and IHC risk scores (Mammostrat® and IHC4), and discuss the current evidence of their clinical use.

U2 - 10.1055/s-0033-1350831

DO - 10.1055/s-0033-1350831

M3 - SCORING: Journal article

C2 - 24771945

VL - 73

SP - 932

EP - 940

JO - GEBURTSH FRAUENHEILK

JF - GEBURTSH FRAUENHEILK

SN - 0016-5751

IS - 9

ER -